Related topics: Contract Manufacturing
Cambrex’s operating profit grew by 24 per cent year-on-year supported by higher volumes of an API using its polymeric drug delivery technology and higher controlled substances and custom development revenues.
The contract manufacturing organisation (CMO) achieved an operating income of $5.6m (€3.8m) on net sales of $57.5m, up 2.1 per cent, but expects a dip to occur in the fourth quarter.
Cambrex attributes this anticipated decline to volatility in the timing of orders and weakness in preclinical and clinical phase projects. Furthermore, price and volume pressures are squeezing Cambrex’s generic active pharmaceutical ingredient (API) business.
Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions